Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.68 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.68 |
| ▸ | RET | P07949 | 1/20 | 0.68 |
| ▸ | HCK | P08631 | 1/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.68 |
| ▸ | FLT4 | P35916 | 1/20 | 0.68 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.68 |
| ▸ | SIK1 | P57059 | 1/20 | 0.68 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.68 |
| ▸ | WNK3 | Q9BYP7 | 1/20 | 0.68 |
| ▸ | DNMT1 | P26358 | 4/20 | 0.59 |
| ▸ | DNMT3A | Q9Y6K1 | 3/20 | 0.59 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679214 | 0.96 | AURKA (0.64) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL678608 | 0.88 | DNMT1 (0.54) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL679112 | 0.88 | AURKA (0.67) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL678875 | 0.88 | AURKA (0.67) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL683837 | 0.88 | DNMT1 (0.54) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL682903 | 0.88 | AURKA (0.67) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL684095 | 0.87 | AURKA (0.69) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL678958 | 0.87 | AURKA (0.54) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL682900 | 0.87 | AURKA (0.54) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL678601 | 0.87 | DNMT1 (0.53) | AURKAAURKBMAPK13CHEK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | claimed |
| JP-2011526912-A | — | — | 2011-10-20 | — | — | JP | claimed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | claimed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | claimed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885MAPK13 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.